I'm not great at science, but I am pretty good at

I'm not great at science, but I am pretty good at math. Dropping the interim analysis level from 127 patients to 50 makes the math very, very difficult. This is just 25 patients that will be treated with LL. Seems like a possible repeat of earlier errors, where measurement groups were too small.

The reasons revolve around money. We need to go faster because we need good news soon because we are short on money. Remember, when NP said we had 20 million shares left, it was factually incorrect. It has already been documented that we have fewer than 6 million. Just because NP says something, that does not make it true.

You say, "Focus is on EUA." I tend to agree, but let's be clear: Most of us are thinking about what an EUA meant for Pfizer and others when it was an EUA issued by the US FDA. The covid EUA we are now talking about is a Brazilian EUA, or equivalent. Quite a different animal in terms of revenue and in terms of US authorization.

It is a difficult road ahead. To say that "cash isn't an issue if needed" is just to ignore all of the published facts.